- Home
- XMTR vs AVBP Comparison
XMTR vs AVBP Comparison
Compare XMTR & AVBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XMTR
- AVBP
- Stock Information
- Founded
- XMTR 2013
- AVBP 2021
- Country
- XMTR United States
- AVBP United States
- Employees
- XMTR N/A
- AVBP N/A
- Industry
- XMTR Industrial Machinery/Components
- AVBP
- Sector
- XMTR Technology
- AVBP
- Exchange
- XMTR Nasdaq
- AVBP NYSE
- Market Cap
- XMTR 1.6B
- AVBP 862.8M
- IPO Year
- XMTR 2021
- AVBP 2024
- Fundamental
- Price
- XMTR $33.45
- AVBP $20.77
- Analyst Decision
- XMTR Buy
- AVBP Strong Buy
- Analyst Count
- XMTR 11
- AVBP 8
- Target Price
- XMTR $34.82
- AVBP $39.00
- AVG Volume (30 Days)
- XMTR 747.5K
- AVBP 487.8K
- Earning Date
- XMTR 08-07-2025
- AVBP 08-13-2025
- Dividend Yield
- XMTR N/A
- AVBP N/A
- EPS Growth
- XMTR N/A
- AVBP N/A
- EPS
- XMTR N/A
- AVBP N/A
- Revenue
- XMTR $573,810,000.00
- AVBP N/A
- Revenue This Year
- XMTR $21.52
- AVBP $85.82
- Revenue Next Year
- XMTR $17.20
- AVBP N/A
- P/E Ratio
- XMTR N/A
- AVBP N/A
- Revenue Growth
- XMTR 19.35
- AVBP N/A
- 52 Week Low
- XMTR $11.32
- AVBP $15.47
- 52 Week High
- XMTR $45.33
- AVBP $36.37
- Technical
- Relative Strength Index (RSI)
- XMTR 52.08
- AVBP 39.60
- Support Level
- XMTR $31.87
- AVBP $20.00
- Resistance Level
- XMTR $34.20
- AVBP $23.27
- Average True Range (ATR)
- XMTR 1.44
- AVBP 1.51
- MACD
- XMTR -0.11
- AVBP -0.49
- Stochastic Oscillator
- XMTR 75.70
- AVBP 13.28
About XMTR Xometry Inc.
Xometry Inc is engaged in providing AI-enabled manufacturing equipment. Its buyers include engineers, product designers, procurement and supply chain personnel, inventors, and business owners. The manufacturing processes offered by the company include CNC Machining, Injection Molding, Urethane Casting, 3D Printing, and Die Casting. The company is organized into two segments referred to as the U.S. and the International. The majority of its revenue is derived from the U.S. segment.
About AVBP ARRIVENT BIOPHARMA INC
ArriVent BioPharma Inc is a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. It seeks to utilize the team's deep drug development experience to maximize the potential of the lead development candidate, furmonertinib, and advance a pipeline of novel therapeutics, such as next-generation antibody-drug conjugates, through approval and commercialization in patients suffering from cancer, with an initial focus on solid tumors.